Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer. 2018

Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Tumor-infiltrating neutrophils (TIN) carry out quite significant but opposite functions in different cancers, and their function in biliary cancer has not been fully characterized. To investigate the prognostic significance of TIN in biliary cancer, a training set (n = 118) and a validation set (n = 127) were involved in this study. TIN were evaluated by immunohistochemical staining of CD66b, and then defined as low (neutrophils <18/high-power field [HPF]) vs high (neutrophils ≥18/HPF). Kaplan-Meier curve, Cox proportional hazards models and receiver operating characteristic curve were used to assess the prognostic significance. TIN was identified as an independent prognostic factor for overall survival in the training set (HR: 4.720; 95% CI: 2.623-8.493; P < .001) which was confirmed in the validation set (HR: 4.993; 95% CI: 2.626-9.492; P < .001). Notably, among patients with stage III and IV disease, those with low TIN could benefit from adjuvant chemotherapy, with a reduced risk of compromised survival compared with those with high TIN (HR: 0.294; 95% CI: 0.099-0.873; P = .047 in the training set; and HR: 0.100; 95% CI: 0.022-0.462; P = .006 in the validation set). In addition, TIN were negatively related to biological pathways as regulation of activated T-cell proliferation and lymphocyte-mediated immunity, and showed a negative correlation with CD8 +  T cells (r = -.324, P < .001). Taken together, our results implicate TIN as an independent marker of prognosis and indicator of patients who would benefit from adjuvant chemotherapy in biliary cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D005706 Gallbladder Neoplasms Tumors or cancer of the gallbladder. Cancer of Gallbladder,Gallbladder Cancer,Cancer of the Gallbladder,Gall Bladder Cancer,Neoplasms, Gallbladder,Bladder Cancer, Gall,Bladder Cancers, Gall,Cancer, Gall Bladder,Cancer, Gallbladder,Cancers, Gall Bladder,Cancers, Gallbladder,Gall Bladder Cancers,Gallbladder Cancers,Gallbladder Neoplasm,Neoplasm, Gallbladder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001650 Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS. Bile Duct Cancer,Cancer of Bile Duct,Cancer of the Bile Duct,Neoplasms, Bile Duct,Bile Duct Cancers,Bile Duct Neoplasm,Cancer, Bile Duct,Cancers, Bile Duct,Neoplasm, Bile Duct

Related Publications

Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2017, Oncoimmunology,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2017, Oncoimmunology,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2018, Oncoimmunology,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
February 2018, Annals of surgery,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
September 2019, BMC cancer,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
July 2023, Journal of cancer research and clinical oncology,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2018, In vivo (Athens, Greece),
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2020, Oncoimmunology,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2018, Journal of Cancer,
Jie Wang, and Xiaobo Bo, and Tao Suo, and Han Liu, and Xiaoling Ni, and Sheng Shen, and Min Li, and Jiejie Xu, and Houbao Liu, and Yueqi Wang
January 2019, Oncoimmunology,
Copied contents to your clipboard!